Literature DB >> 12749280

Premalignant lesions and conditions for gastric adenocarcinoma: diagnosis, management and surveillance guidelines.

Ioannis Kyrlagkitsis1, Demetrios G Karamanolis.   

Abstract

Despite universal trends of declining mortality rates, gastric cancer remains a major health problem. The advent of endoscopy has made a major impact in the diagnosis and management of early gastric cancer as well as of the premalignant lesions of the stomach. Nevertheless the disagreement between Japanese and Western histopathologists regarding the nomenclatures of the gastric precancerous lesions resulted in different recommendations and therapeutic guide lines. On this background we review the current concepts related to premalignant lesions, especially intestinal metaplasia and gastric dysplasia as well as the critical role of Helicobacter pylori in the evolution of these lesions. Additionally, this extensive review deals with the majority of precancerous conditions related to gastric adenocarcinoma and provides surveillance and therapeutic guidelines.

Entities:  

Mesh:

Year:  2003        PMID: 12749280

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

Review 1.  Pathology of gastric intestinal metaplasia: clinical implications.

Authors:  Pelayo Correa; M Blanca Piazuelo; Keith T Wilson
Journal:  Am J Gastroenterol       Date:  2010-03       Impact factor: 10.864

2.  The 7th AJCC/UICC TNM staging system may be not suitable in predicting prognosis of synchronous multiple gastric carcinoma patients with D2 gastrectomy.

Authors:  Xiaolong Tang; Zhongmin Lan; Yingtai Chen; Jianwei Zhang; Xu Che; Chengfeng Wang
Journal:  Tumour Biol       Date:  2015-01-08

3.  Alcoholic Liver Disease Is Associated with an Increased Risk of Gastric Cancer.

Authors:  Tae Hoon Ha; Byeong Gwan Kim; Donghyong Jeong; Sohee Oh; Won Kim; Yong Jin Jung; Dong Won Ahn; Ji Bong Jeong; Ji Won Kim; Kook Lae Lee; Seong-Joon Koh
Journal:  Dig Dis Sci       Date:  2016-10-26       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.